Respiree is a health tech company established in 2019. It specializes in AI/ML to provide targeted predictions and diagnosis using breath-cardio informatics. The company's flagship iRIS platform leverages data from the EHR and a proprietary US-patented and FDA-cleared sensor to longitudinally measure and track disease progression. Respiree is now available in the US and Asia-Pacific, and has secured commercial tie-ups with global channel partners to expand its offerings. The product is CE marked and has received regulatory clearances in Australia from the Therapeutic Goods Administration, and the United States Food and Drug Administration (FDA) has granted it the 510(k) clearance.
At 09 March 2022, Respiree closed a SGD4.70M Seed Round investment, with participation from She1K, Oriza Holdings, and SEEDS Capital.
